Presentation is loading. Please wait.

Presentation is loading. Please wait.

Heart Failure Events and All-cause Death in New Users of SGLT-2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups.

Published byBethany Webb Modified over 6 years ago

Similar presentations

Presentation on theme: "Heart Failure Events and All-cause Death in New Users of SGLT-2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups."— Presentation transcript:

1 Heart Failure Events and All-cause Death in New Users of SGLT-2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups in 5 countries and >300,000 patients: The CVD-REAL Study Anna Norhammar1, Matthew Cavender2, Kåre Birkeland3, Kamlesh Khunti4, John Wilding5, Niklas Hammar6, Johan Bodegard7, Marcus Thuresson8, Peter Fenici9, Mikhail Kosiborod10 on behalf of the CVD-REAL Investigators and Study Group 1Karolinska Institute, Department of Medicine, Cardiology Unit, Stockholm, Sweden; 2University of North Carolina Hospitals, Chapel Hill, United States of America; 3University of Oslo and Oslo University Hospital, Oslo, Norway; 4University of Leicester, Leicester, United Kingdom; 5University of Liverpool, Liverpool, United Kingdom; 6AstraZeneca, Gothenburg, Sweden; 7AstraZeneca, Oslo, Norway; 8Statisticon AB, Uppsala, Sweden; 9AstraZeneca, Cambridge, United Kingdom; 10Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, United States of America

2 Presenter Disclosure Disclosures
Consultant and honorarium: AstraZeneca, Boehringer-Ingelheim, Lilly, Novo Nordisk, MSD Sweden Acknowledgements This study was supported by AstraZeneca Researchers from AstraZeneca participated in the CVD-REAL study team and interpretation of data Editorial support was provided by Nicola Truss PhD, inScience Communications, Springer Healthcare, and was funded by AstraZeneca

3 Background Two large RCTs have shown that sodium-glucose cotransporter-2 inhibitors (SGLT-2i) empagliflozin and canagliflozin reduce the risk of major adverse CV events, in a T2D diabetes population primarily with established CV disease (CVD), suggesting a class effect1,2 Presented at ADA2017 by David R. Matthew 1Zinman B et al. N Engl J Med. 2015;373: ; 2Neal B et al. N Engl J Med. 2017; DOI: /NEJMoa

4 Background (2) In CVD-REAL, a multinational, observational study with >1.3 million T2D patients, we demonstrated that SGLT-2i were associated with lower risk of death and heart failure vs other glucose- lowering drugs (GLDs) 1,2 Whether the associated benefits of SGLT-2i differ among patients with various demographic, clinical and treatment characteristics is unknown 1Kosiborod M et al. Circulation 2017;136:249–259; 2Cavender M et al. Diabetes, 2017;66(Suppl 1):A [abstract 377-OR]

5 Aim Evaluate if the association between SGLT-2i and heart failure events, all-cause death and the composite of heart failure and death is modified by demographic, clinical and treatment factors

6 Data Sources: Health records from five countries
Truven MarketScan Claims database - United States National full-population registries - Denmark National full- population registries - Norway National full-population registries - Sweden Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN) - United Kingdom

7 Methods Inclusion criteria
New users of SGLT-2i or new users of other GLDs Established T2D ≥18 years old >1 year historical data prior to index date Exclusion criteria Type 1 or gestational diabetes Study period with a mean follow-up time of 225 days Outcomes Heart failure events All-cause death Composite of heart failure events or death

8 Methods (2) Subgroups studied: Demographics Co-morbidities
Age (<65 years or ≥65 years), sex Co-morbidities chronic kidney disease Concomitant therapies Cardiovascular therapies: Angiotensin receptor blocker (ARB)/angiotensin-converting enzyme inhibitors (ACEi), beta blockers, aldosterone antagonists, diuretics, statins Glucose-lowering therapies: Insulin, sulphonylureas

9 Statistical methods Non-parsimonious propensity score developed in each country to estimate the likelihood of initiating an SGLT-2i Patients matched 1:1 by propensity score In the matched cohort: Patients stratified by key-subgroups Event rates for heart failure, all-cause death and composite were calculated Cox proportional hazards models used to estimate the hazard ratios (HRs) and 95% confidence intervals (CI) for all outcomes, adjusted for baseline risk factors and treatments Meta-analysis used to pool hazard ratios from each country and obtain summary weighted point estimates

10 Patient population 1,366,731 new users of SGLT-2 inhibitor or other GLD fulfilling the eligibility criteria 164,501 SGLT-2 inhibitor 1,202,230 Other GLD 7% (11,423) excluded during 1:1 match process 87% (1,049,152) excluded during 1:1 match process 1:1 propensity match 153,078 SGLT-2 inhibitor 153,078 Other GLD Final study population

11 Baseline Characteristics
Characteristics, n (%) SGLT-2i (N=153,078) Other GLD (N=153,078) Age, years, mean (SD) 57.0 (10.0) 57.0 (10.6) Women 67,801 (44.3) 68,158 (44.5) Established CVD 19,529 (12.8) 19,764 (12.9) Acute myocardial infarction 3,651 (2.4) 3,733 (2.4) Unstable angina 2,477 (1.6) 2,513 (1.6) Heart failure 4,635 (3.0) 4,677 (3.1) Atrial fibrillation 5,556 (3.6) 5,619 (3.7) Stroke 6,256 (4.1) 6,309 (4.1) Peripheral artery disease 4,924 (3.2) 4,920 (3.2) Microvascular disease 41,496 (27.1) 41,467 (27.1) Chronic kidney disease 3,702 (2.4) 3,865 (2.5)

Download ppt "Heart Failure Events and All-cause Death in New Users of SGLT-2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups."

Similar presentations

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.

Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
International comparison of outcomes among 140 887 survivors after acute myocardial infarction: real-world evidence from electronic health and administrative.

International comparison of outcomes among survivors after acute myocardial infarction: real-world evidence from electronic health and administrative.
P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Oral drugs for type 2 diabetes and all cause mortality in General.

P H Y S I C I A N S ’ A C A D E M Y F O R C A R D I O V A S C U L A R E D U C A T I O N Oral drugs for type 2 diabetes and all cause mortality in General.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Martial Hamon 1, Steven Marso 2, Sunil Rao 3, Marco Valgimigli 4, Freek Verheugt 5, Anthony Gershlick 6, Yamei Wang 8, Gabriel Steg 7, Efthymios Deliargyris.

Martial Hamon 1, Steven Marso 2, Sunil Rao 3, Marco Valgimigli 4, Freek Verheugt 5, Anthony Gershlick 6, Yamei Wang 8, Gabriel Steg 7, Efthymios Deliargyris.
Multiple risk factors raise ischaemic stroke risk comparable to AF in the elderly: A large Chinese insurance analysis from 425,600 Chinese individuals.

Multiple risk factors raise ischaemic stroke risk comparable to AF in the elderly: A large Chinese insurance analysis from 425,600 Chinese individuals.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.

Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.

Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-72.

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
ALLHAT 6/5/2006 - 1 CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.
6/5/2006 - 1 1 CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Rosuvastatin 10 mg n=2514 Placebo n=2497 2 to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.

Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.

Similar presentations

Ads by Google